EUVIMEDEUVIMED entdecken
Crossref

Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress

Mei-Qi Wang, Kai-Hui Zhang, Fang-Le Liu, Rui Zhou, Yun Zeng, A-Li Chen, Yang Yu, Quan Xia, Chen-Chen Zhu, Chao-Zhan Lin

Phytomedicine · 2024-01 · 122 · 155124

DOI: 10.1016/j.phymed.2023.155124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024-01. Verfasst von Mei-Qi Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. Hauptthemen laut MEDLINE: Cholestasis, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Department of Education of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cholestatic liver diseases (CLD) comprise a variety of disorders of bile formation, which causes chronic exposure to bile acid (BA) in the liver generally and results in hepatotoxicity and progressive hepatobiliary injury. Wedelolactone (7-methoxy-5, 11, 12-trihydroxy-coumestan, WED), the natural active compound derived from Ecliptae Herba, has been reported with valuable bioactivity for liver protection. Nevertheless, the effect of WED on cholestatic liver injury (CLI) remains unexplored. PURPOSE: The present study aims to elucidate the protective effect of WED on Alpha-naphthylisothiocyanate (ANIT)-induced CLI mice, and to investigate its potential pharmacological mechanism. METHODS: The anit-cholestatic and hepatoprotective effects of WED were evaluated in ANIT-induced CLI mice. Non-targeted metabolomics study combined with ingenuity pathway analysis (IPA) was used to explore the key mechanism of WED. The BA metabolic profile in enterohepatic circulation was analyzed to evaluate the effect of WED in regulating BA metabolism. Furthermore, molecular dynamics (MD) simulation and cellular thermal shift assay (CETSA) were used to simulate and verify the targeting activation of WED on the Farnesoid X receptor (FXR). The core role of FXR in WED promoting BA transportation, and alleviating BA accumulation-induced hepatotoxicity was further evaluated in WT and FXR knockout mice or hepatocytes. RESULTS: WED dose-dependently alleviated ANIT-induced cholestasis and liver injury in mice, and simultaneously suppressed the signaling pathway of nuclear factor-kappa B/nuclear factor-erythroid 2-related factor 2 (NF-κB/NRF2) to relieve inflammation and oxidative stress. At the metabolite level, WED improved the metabolic disorder in CLI mice focusing on the metabolism of BA, arachidonic acid, and glycerophospholipid, that closely related to the process of BA regulation, inflammation, and oxidative damage. WED targeting activated FXR, which then transcribed its target genes, including the bile salt export pump (BSEP) and the BA transporter, and subsequently increased BA transportation to restore the damaged enterohepatic circulation of BA. Meanwhile, WED alleviated hepatic BA accumulation and protected the liver from BA-induced damage via NF-κB/NRF2 signaling pathway. Furthermore, FXR deficiency suppressed the protective effect of WED in vitro and in vivo. CONCLUSION: WED regulated BA metabolism and alleviated hepatic damage in cholestasis. It protected the liver according to adjusted BA transportation and relieved BA accumulation-related hepatotoxicity via FXR-bile acid-NF-κB/NRF2 axis. Our study provides novel insights that WED might be a promising strategy for cholestatic liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisChemical and Drug Induced Liver InjuryMiceAnimalsNF-kappa BNF-E2-Related Factor 2Bile Acids and SaltsLiverInflammationOxidative StressCoumarins

Stichwörter der Autor:innen

Anti-inflammation and antioxidantBile acidCholestatic liver injuryFXRNF-κB/NRF2 signalingWedelolactone

Substanzen

NF-kappa BNF-E2-Related Factor 2Bile Acids and SaltswedelolactoneCoumarins

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
  • School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou, China.
  • School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: xia@gzucm.edu.cn.
  • School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: zhucc@gzucm.edu.cn.
  • School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: linchaozhan@gzucm.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Department of Education of Guangdong Province

Zitieren

APA

Wang, M. Q., Zhang, K. H., Liu, F. L., Zhou, R., Zeng, Y., Chen, A. L., Yu, Y., Xia, Q., Zhu, C. C., & Lin, C. Z. (2024). Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress. Phytomedicine, 122, 155124. https://doi.org/10.1016/j.phymed.2023.155124

Vancouver

Wang MQ, Zhang KH, Liu FL, Zhou R, Zeng Y, Chen AL, et al. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress. Phytomedicine. 2024;122:155124. doi:10.1016/j.phymed.2023.155124

BibTeX
@article{Wang2024,
  author = {Wang, Mei-Qi and Zhang, Kai-Hui and Liu, Fang-Le and Zhou, Rui and Zeng, Yun and Chen, A-Li and Yu, Yang and Xia, Quan and Zhu, Chen-Chen and Lin, Chao-Zhan},
  title = {Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress},
  journal = {Phytomedicine},
  year = {2024},
  volume = {122},
  pages = {155124},
  doi = {10.1016/j.phymed.2023.155124}
}
Kostenlos starten →